Navigation Links
Genomind to Participate in National Alliance on Mental Illness (NAMI) 2012 National Convention
Date:6/28/2012

Chalfont, PA (PRWEB) June 28, 2012

Genomind will demonstrate support for the millions of Americans affected by mental illness by participating in the National Alliance on Mental Illness (NAMI) 2012 National Convention. This marks the second year Genomind is appearing at NAMI; last year the company gave a presentation on emerging technologies in mental health.

The theme of this year’s meeting is “Think, Learn and Live: Wellness, Resiliency and Recovery.” It is a message that resonates with Genomind since the company was founded with the ultimate goal of improving patients’ lives - particularly the lives of patients with difficult-to-treat psychiatric conditions. Its core product, the Genecept™ Assay, is a simple to use, saliva-based tool to inform clinician treatment decision-making for a range of psychiatric disorders, including depression, bipolar disorder, schizophrenia, anxiety disorders, OCD and ADHD.

“We are proud to support NAMI,” said Dr. Jay Lombard, chief scientific officer and co-founder of Genomind. “It is a wonderful organization that is devoted to helping improve the lives of the over 1 in 4 adults and 1 in 10 children across America affected by mental illness. We share NAMI’s commitment to bringing advancements in research to clinical practice and patients.”

The convention will be held at the Sheraton Seattle from June 27-30. Genomind will exhibit the Genecept Assay in Booth 206. For more information about this year’s convention, please visit http://www.nami.org/template.cfm?section=convention.

About NAMI
NAMI is the nation's largest grassroots mental health organization dedicated to building better lives for the millions of Americans affected by mental illness. NAMI advocates for access to services, treatment, supports and research and is steadfast in its commitment to raising awareness and building a community of hope. For more information, please visit http://www.nami.org/.

About Genomind
Genomind is a personalized medicine company, comprised of innovative researchers and expert leaders in psychiatry and neurology. Genomind is committed to discovery of the underlying causes of neuropsychiatric disorders and supports the development of personalized medicine that improves patients’ lives. Genomind was founded by Ronald I. Dozoretz, MD, a psychiatrist who has devoted his career to improving mental health. Jay Lombard, DO, a neurologist and co-founder of Genomind, is a critically acclaimed author and nationally recognized thought leader in neuropsychiatry practice and research. Learn more at http://www.genomind.com.

Read the full story at http://www.prweb.com/releases/2012/6/prweb9650703.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Medical Experts Who Participated in CSL Behrings Key Issues Dialogue Prefer Albumin for Fluid Management
2. Avanir Pharmaceuticals to Participate in Citi 2012 Global Health Care Conference
3. ViroPharma to Participate in Two December Healthcare Investor Conferences
4. National Defense Industrial Association's (NDIA) 2012 Biosurveillance Conference To Feature Keynote Speaker Laurie Garrett, Pulitzer Prize Winner and Bestselling Author
5. DOE-CEA Partnership Awards Mentoring Services to Finalists in National Clean Energy Business Plan Competition
6. International Probiotics Association Excited To Learn The FDA Has Decided To Issue A New, Revised NDI Draft Guidance
7. National Defense Industrial Association (NDIA) Opens Registration For 2012 Biosurveillance Conference, Set For August 27-28 in Washington, D.C.
8. Promoting the States Quality of Life, New Jersey Symphony Orchestra to Perform at BIO International Convention
9. International Survey of T2* Cardiovascular Magnetic Resonance in Thalassemia
10. Fortis Vice President of Nursing Robert Anders Named Academy of Nursing Education Fellow by National League for Nursing
11. OrthoAccel Technologies, Inc. Names U.S. National Sales Director
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... Foundation President Andi Purple announced Dr. Suneel I. Sheikh, the co-founder, CEO ... ASTER Labs ), Inc. has been selected for membership in ARCS Alumni ...
(Date:10/11/2017)... a leading provider of patient support solutions, has announced the ... which will launch this week. The VMS CNEs will address ... enhance the patient care experience by delivering peer-to-peer education programs ... to help women who have been diagnosed and are being ... ...
(Date:10/10/2017)... ... October 10, 2017 , ... San Diego-based team building ... corporate rebranding initiative announced today. The bold new look is part of a ... company moves into a significant growth period. , It will also expand its service ...
(Date:10/10/2017)... , Oct. 10, 2017 SomaGenics announced the ... NIH to develop RealSeq®-SC (Single Cell), expected to be ... small RNAs (including microRNAs) from single cells using NGS ... the need to accelerate development of approaches to analyze ... "New techniques for measuring levels of mRNAs ...
Breaking Biology Technology:
(Date:4/5/2017)... SEATTLE , April 5, 2017  The Allen ... the Allen Cell Explorer: a one-of-a-kind portal and dynamic ... large-scale 3D imaging data, the first application of deep ... edited human stem cell lines and a growing suite ... the platform for these and future publicly available resources ...
(Date:4/3/2017)... April 3, 2017  Data captured by ... platform, detected a statistically significant association between ... to treatment and objective response of cancer ... to predict whether cancer patients will respond ... as well as to improve both pre-infusion potency ...
(Date:3/29/2017)... CHICAGO , March 29, 2017  higi, the ... ecosystem in North America , today ... Partners and the acquisition of EveryMove. The new investment ... extensive set of tools to transform population health activities ... and lifestyle data. higi collects and secures ...
Breaking Biology News(10 mins):